Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children and Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain.
COVID-19
SARS-CoV-2
antibody
household
prevalence
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
received:
21
08
2020
accepted:
10
11
2020
pubmed:
13
11
2020
medline:
25
6
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
Susceptibility of children and adults to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and persistence of antibody response to the virus after infection resolution remain poorly understood, despite their significant public health implications. A prospective cross-sectional seroprevalence study with volunteer families that included at least 1 first-reported adult case positive by SARS-CoV-2 by polymerase chain reaction (PCR) and at least 1 child aged <15 years living in the same household under strict home confinement was conducted in the metropolitan Barcelona Health Region, Spain, during the pandemic period 28 April 2020-3 June 2020. All household members were tested at home using a rapid SARS-CoV-2 antibody assay with finger prick-obtained capillary blood. A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 412 adults) were enrolled. SARS-CoV-2 seroprevalence rates were 17.6% (118 of 672) in children and 18.7% (77 of 335) in adult contacts (P = .64). Among first-reported cases, seropositivity rates varied from 84.0% in adults previously hospitalized and tested within 6 weeks since the first positive PCR result to 31.5% in those not hospitalized and tested after that lag time (P < .001). Nearly all (99.9%) positive children were asymptomatic or had mild symptoms. Children appear to have similar probability as adults to become infected by SARS-CoV-2 in quarantined family households but remain largely asymptomatic. Adult antibody protection against SARS-CoV-2 seems to be weak beyond 6 weeks post-infection confirmation, especially in cases that have experienced mild disease.
Sections du résumé
BACKGROUND
Susceptibility of children and adults to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and persistence of antibody response to the virus after infection resolution remain poorly understood, despite their significant public health implications.
METHODS
A prospective cross-sectional seroprevalence study with volunteer families that included at least 1 first-reported adult case positive by SARS-CoV-2 by polymerase chain reaction (PCR) and at least 1 child aged <15 years living in the same household under strict home confinement was conducted in the metropolitan Barcelona Health Region, Spain, during the pandemic period 28 April 2020-3 June 2020. All household members were tested at home using a rapid SARS-CoV-2 antibody assay with finger prick-obtained capillary blood.
RESULTS
A total of 381 family households including 381 first-reported PCR-positive adult cases and 1084 contacts (672 children, 412 adults) were enrolled. SARS-CoV-2 seroprevalence rates were 17.6% (118 of 672) in children and 18.7% (77 of 335) in adult contacts (P = .64). Among first-reported cases, seropositivity rates varied from 84.0% in adults previously hospitalized and tested within 6 weeks since the first positive PCR result to 31.5% in those not hospitalized and tested after that lag time (P < .001). Nearly all (99.9%) positive children were asymptomatic or had mild symptoms.
CONCLUSIONS
Children appear to have similar probability as adults to become infected by SARS-CoV-2 in quarantined family households but remain largely asymptomatic. Adult antibody protection against SARS-CoV-2 seems to be weak beyond 6 weeks post-infection confirmation, especially in cases that have experienced mild disease.
Identifiants
pubmed: 33180914
pii: 5979490
doi: 10.1093/cid/ciaa1721
pmc: PMC7717181
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e970-e977Investigateurs
Cristina Adroher
(C)
Laia Alsina
(L)
Sara Ajanovic
(S)
Ainhoa Andueza
(A)
Sara Arias
(S)
Nuria Balanza
(N)
Barbara Baro
(B)
Elisenda Bonet-Carne
(E)
Joana Claverol
(J)
Marta Cubells
(M)
Claudia Fortuny
(C)
Aleix Garcia-Miguel
(A)
Eduard Gratacos
(E)
Maria Hernandez
(M)
Monica Morales
(M)
Felipe Pérez-Soler
(F)
María Ríos
(M)
Pere Millat
(P)
Gemma Pons
(G)
Francesc Torrents
(F)
Iris Uribesalgo
(I)
Anna Valls
(A)
Rosauro Varo
(R)
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
J Microbiol Immunol Infect. 2020 Jun;53(3):371-372
pubmed: 32147409
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Clin Infect Dis. 2020 Nov 5;71(8):1953-1959
pubmed: 32382743
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
N Engl J Med. 2020 Jun 11;382(24):2302-2315
pubmed: 32289214
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
JAMA Pediatr. 2020 Apr 8;:
pubmed: 32267485
Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
Emerg Infect Dis. 2020 Nov;26(11):2791-2793
pubmed: 32917292
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ Glob Health. 2020 May;5(5):
pubmed: 32467353
Pediatrics. 2020 Jun;145(6):
pubmed: 32179660
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
BMJ. 2020 May 22;369:m1985
pubmed: 32444460